Gilead Sciences, Inc. presented initial data from the phase 2 ATLAS trial in nonalcoholic steatohepatitis (NASH) at
A prespecified interim analysis of the ongoing Phase 3 REGENERATE study, evaluating obeticholic acid (OCA) in the ...
Immunocre announced the U.S. FDA has granted Fast Track Designation to lead T Cell Receptor (TCR) asset tebentafusp
Viking Therapeutics will present updated data from a 12-week Phase 2 study of VK2809 in patients with non-alcoholic
Dicerna Pharmaceuticals presented updated data from its ongoing PHYOX1 Phase 1 clinical trial evaluating DCR-PHXC, ...
No results found.